News

Index of Companies

Valuable resources on the Internet for clinical trial professionals and potential participants.

Contract Research Services

Subject Recruitment

Institutional Review Boards

Consulting

Laboratory Supplies

Paris, May 3, 2006– BioAlliance Pharma SA (Euronext Paris: BIO), an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections, announced today that its new, wholly owned sales and marketing subsidiary, Laboratoires BioAlliance Pharma SAS, has begun formal operations. Laboratoires BioAlliance Pharma will be responsible for all BioAlliance sales and marketing activities, initially focused on the launch of the company's first product Loramyc(R), for treatment of oropharyngeal candidiasis, an oral fungus found in association with immune compromised patients. Following regulatory approval expected in late 2006, the product will be launched first in France, followed by additional launches in other selected European countries as approvals are obtained under the mutual recognition procedure. The company filed for Loramyc marketing authorization approval (MAA) in September 2005. The new subsidiary will be headed by BioAlliance Pharma CEO, Dominique Costantini, MD. Florence Dupr?, vice president of sales and marketing and Alain Maquin, Head Pharmacist are the other directors.

Information Technology

Selected oncology Web sites to assist readers in becoming more informed about cancer and available clinical trials in this therapeutic area.

Lance Armstrong to Receive Special Recognition Award on Monday, June 5

Genzyme Pharmaceuticals, a business unit of Genzyme Corporation, and Brookwood Pharmaceuticals, Inc., today announced a broad collaboration to develop novel drug delivery solutions, with an initial focus on peptide delivery.

Unique Informatics Technology Improves Workflow Flexibility and Data Integration

Tools for Clinical Trials Professionals

TOPRA hosts another successful conference

Images from the exhibition and seminar floors at the 18th annual event in Paris, the most well-attended meeting to date.

Company Relies on Phase Forward's InForm EDC Solution to Accelerate Clinical Data Collection and Analysis

The collaboration will provide Datatrial and Nexus' clients with more effective management and delivery of oncology trials

entimICER DARE dramatically improves how pharmaceutical companies can manage, analyze, and report on clinical data.

Jean-Francois Dehecq, sanofi-aventis, France, noted that innovation is founded in strong science and research, is critical for success and competitiveness, and contributes to the health of patients and wealth of society.

Opening of new frontiers in the diagnosis of allergy to more than 20 different metals and a large number of allergens from a single blood sample

Oracle Introduces Oracle® Clinical Data Repository to Help Life Sciences Organizations Accelerate Decision Making, Reduce Risk and Streamline Compliance - Pharmaceutical Manufacturer Boehringer Ingelheim Begins Implementation

Cognitive Drug Research (CDR) has formed an alliance with Pharma Services Network to further their business in North America.

ACT had a chance to catch up with Dr. Rose, MD, MS, Head Pediatrics, F. Hoffmann-La Roche Ltd, Pharmaceutical Division.

Phase Forward Senior Professional Barry Burnstead Honored with Membership Lifetime Award

Chief Medical Officer Ed Ikeguchi to Present on UK’s Nationwide EDC Deployment; Senior Director Anne Zielinski to Highlight Data Integration Techniques

Take a pictorial tour of Paris with the editors of Applied Clinical Trials

Program Co-Chairs Iman Barilero, Johnson & Johnson PRD, and Marie Dray, International Regulatory Affairs Group USA, opened the first plenary session with introductions, sharing their vision of what the 18th Annual DIA EuroMeeting is all about: continuing themes throughout the meeting, including pediatrics, advanced therapies, technology platform, pharmacovigilance, risk management planning, and the involvement of patient groups.